Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Two case reports with supporting ex vivo evidence raise a mechanistic hypothesis about LHRH agonists and meningioma growth, but lack controlled comparison, prospective data, or clinical outcome quantification to establish causation or clinical risk.
World Journal of Pharmacy and Pharmaceutical Sciences
A systematic review of diagnostic delays and pathophysiology in lean PCOS that synthesizes clinical trials and mechanistic insights, but reports no primary trial data, effect sizes, or comparative outcomes to support clinical decision-making.
World Journal of Pharmacy and Pharmaceutical Sciences
This is a systematic review that synthesizes existing evidence on lean PCOS pathophysiology and diagnostic delays, but reports no primary data, effect sizes, or comparative trial results to support actionable clinical recommendations.
An expert consensus opinion article evaluating the rationale for renaming PCOS to PMOS, supported by a global consensus process and evidence review, rather than reporting new primary data.
A narrative review synthesizing current evidence on hypercortisolism in Type 2 diabetes, recommending targeted case-finding strategy and DST screening approach rather than universal screening.
A rigorous multicenter RCT with adequate follow-up that confirms prior findings but shows adrenalectomy offers limited benefit beyond hypertension for metabolic and QoL outcomes in MACS, with wide confidence intervals and modest effect sizes.
Retrospective single-center observational audit without a comparator or control group, describing clinical and surgical outcomes in a tertiary-care cohort with acknowledged methodological limitations (no adjustment for multiple comparisons, unequal strata, non-uniform follow-up) that preclude causal inference.